EGFR and small cell lung carcinoma: The majority of de novo EGFR-mt SCLC are resistant to EGFR-TKI therapy, compared with EGFR-mt NSCLC21, which may be due to focusing much more on the driver gene “EGFR” and neglecting of passenger mutations’ effect.